Carterra Ships First Ultra Biosensor Platform, Achieves Record Growth in 2024

Carterra Inc., a global leader in high-throughput biology, has announced the sale and shipment of its first Carterra Ultra™ biosensor platform. Unveiled in September 2024, the Ultra instrument offers a comprehensive range of applications for both small and large molecules, featuring gold-standard SPR detection, high-throughput capabilities, and minimal sample requirements. This milestone marks the culmination of a record-breaking year for Carterra, characterized by exceptional double-digit revenue growth.

Ultra Biosensor Platform: Revolutionizing Drug Discovery

The Carterra Ultra™ biosensor platform is designed to meet the evolving needs of drug and vaccine discovery groups. “We understand that spending and investment in drug discovery technologies—especially capital equipment like ours—has been challenged the last couple of years,” said Tim Germann, Carterra’s Chief Commercial Officer. “Even so, drug and vaccine discovery groups are focused more than ever on going faster and spending less money to bring life-saving therapies to market—that’s exactly what Carterra platforms enable.”

Advanced Capabilities and Applications of the Ultra Platform

Capable of characterizing molecules as small as 100 Daltons, the Ultra platform is being utilized by initial customers to analyze molecular glues, PROTACS, DNA-encoded libraries (DELs), kinases, membrane proteins, and ligandability. The Ultra also boasts increased speed of analysis, flexible referencing, and new screening software for fragment and small molecule applications. For the first time, researchers can conduct fragment-based lead discovery, small-molecule analysis, and large molecule protein-protein interactions, including on- and off-target measurements, at an industrial scale.

Showcasing Groundbreaking Data at Upcoming Conferences

Leading biopharma scientists will present groundbreaking new data generated with the Carterra Ultra platform at the SLAS2025 International Conference & Exhibition and Drug Discovery Chemistry 2025, both to be held in San Diego, California. These presentations will highlight the platform’s impact on advancing fragment and small molecule drug discovery, demonstrating how Ultra enables innovative workflows and accelerates discovery timelines.

Carterra’s Commitment to Innovation and Growth

“We are thrilled to ship the Ultra platform ahead of schedule—our second new product in as many years,” commented Chris Silva, Vice President of Marketing and Product at Carterra. “Our development teams are hard at work, hitting their stride. I think it’s safe to assume that there’s plenty more where that came from.”

How do you think the Carterra Ultra™ biosensor platform will impact the future of drug discovery and development?